REPLIGEN CORP (RGEN) Quick Ratio
- Quick ratio · latest quarter: Value 7.30×; Formula and calculation Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30..
Quick ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Quick ratio · latest quarter | 7.30× | Cash, cash equivalents, current marketable securities and trade receivables / current liabilities. Period ending 2026-06-30. $968.16M ÷ $132.66M ≈ 7.30× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Cash, securities and trade receivables | 968.16M USD | Cash and Cash Equivalents, at Carrying Value · Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current · Accounts Receivable, after Allowance for Credit Loss, Current |
| Current obligations | 132.66M USD | Liabilities, Current |
| Cash and equivalents | 606.78M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 203.67M USD | Marketable Securities, Current · Debt Securities, Available-for-sale, Current · Available-for-sale Securities, Current |
| Customer receivables | 157.71M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory · excluded from quick assets | 186.60M USD | Inventory, Net |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Cash, securities and trade receivables (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory · excluded from quick assets (USD) | Quick ratio |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $968.16M | $132.66M | $606.78M | $203.67M | $157.71M | $186.60M | 7.30× |
| 2026-03-31 | $936.08M | $126.21M | $582.65M | $201.88M | $151.55M | $179.26M | 7.42× |
| 2025-12-31 | $926.22M | $135.83M | $566.02M | $201.61M | $158.59M | $170.46M | 6.82× |
| 2025-09-30 | (m) | $131.14M | $748.75M | (m) | $148.97M | $160.32M | (m) |
| 2025-06-30 | (m) | $123.01M | $708.86M | (m) | $156.95M | $155.86M | (m) |
| 2025-03-31 | (m) | $152.00M | $697.23M | (m) | $147.41M | $153.11M | (m) |
| 2024-12-31 | (m) | $126.79M | $757.36M | (m) | $134.12M | $142.96M | (m) |
| 2024-09-30 | (m) | $108.37M | $783.96M | (m) | $129.03M | $182.47M | (m) |
| 2024-06-30 | (m) | $174.31M | $809.15M | (m) | $123.25M | $190.53M | (m) |
| 2024-03-31 | (m) | $178.31M | $780.62M | (m) | $115.77M | $198.03M | (m) |
| 2023-12-31 | (m) | $158.16M | $751.32M | (m) | $124.16M | $202.32M | (m) |
| 2023-09-30 | (m) | $363.36M | $630.78M | (m) | $106.16M | $211.37M | (m) |
| 2023-06-30 | (m) | $373.58M | $603.66M | (m) | $120.30M | $240.87M | (m) |
| 2023-03-31 | (m) | $405.32M | $516.61M | (m) | $133.49M | $244.70M | (m) |
| 2022-12-31 | (m) | $404.20M | $523.46M | (m) | $116.25M | $238.28M | (m) |
| 2022-09-30 | (m) | $410.70M | $573.36M | (m) | $117.64M | $242.69M | (m) |
| 2022-06-30 | (m) | $423.52M | $596.51M | (m) | $121.05M | $239.12M | (m) |
| 2022-03-31 | (m) | $424.33M | $584.64M | (m) | $122.44M | $213.78M | (m) |
| 2021-12-31 | (m) | $375.26M | $603.81M | (m) | $117.42M | $184.49M | (m) |
| 2021-09-30 | (m) | $349.44M | $621.10M | (m) | $122.05M | $156.16M | (m) |
| 2021-06-30 | (m) | $332.34M | $734.33M | (m) | $102.66M | $135.51M | (m) |
| 2021-03-31 | (m) | $313.33M | $711.32M | (m) | $90.21M | $109.52M | (m) |
| 2020-12-31 | (m) | $318.96M | $717.29M | (m) | $71.26M | $95.03M | (m) |
| 2020-09-30 | (m) | $50.98M | $553.30M | (m) | $55.83M | $78.53M | (m) |
| 2020-06-30 | (m) | $44.40M | $560.36M | (m) | $48.78M | $69.93M | (m) |
| 2020-03-31 | (m) | $41.85M | $529.52M | (m) | $44.73M | $61.78M | (m) |
| 2019-12-31 | (m) | $48.31M | $528.39M | (m) | $43.07M | $54.83M | (m) |
| 2019-09-30 | (m) | $38.77M | $513.45M | (m) | $41.97M | $51.58M | (m) |
| 2019-06-30 | (m) | $140.91M | $208.89M | (m) | $43.05M | $51.27M | (m) |
| 2019-03-31 | (m) | $130.28M | $196.13M | (m) | $39.34M | $44.92M | (m) |
| 2018-12-31 | (m) | $129.84M | $193.82M | (m) | $33.02M | $42.26M | (m) |
| 2018-09-30 | (m) | $129.85M | $190.30M | (m) | $30.78M | $42.28M | (m) |
| 2018-06-30 | (m) | $121.12M | $175.61M | (m) | $31.71M | $40.95M | (m) |
| 2018-03-31 | (m) | $20.32M | $173.88M | (m) | $29.35M | $40.12M | (m) |
| 2017-12-31 | (m) | $25.21M | $173.76M | (m) | $27.59M | $39.00M | (m) |
| 2017-09-30 | $189.15M | $118.45M | $159.67M | $0.00 | $29.48M | $38.66M | 1.60× |
| 2017-06-30 | $167.07M | $16.52M | $142.21M | $2.74M | $22.11M | $26.09M | 10.11× |
| 2017-03-31 | $159.55M | $13.75M | $129.66M | $12.18M | $17.71M | $23.96M | 11.60× |
| 2016-12-31 | $156.97M | $21.07M | $122.23M | $19.55M | $15.19M | $24.70M | 7.45× |
| 2016-09-30 | $193.87M | $20.19M | $157.65M | $21.06M | $15.15M | $24.46M | 9.60× |
| 2016-06-30 | $192.88M | $21.35M | $172.62M | $9.18M | $11.07M | $23.20M | 9.03× |
| 2016-03-31 | $82.27M | $15.82M | $53.21M | $16.48M | $12.57M | $21.32M | 5.20× |
| 2015-12-31 | $83.07M | $18.78M | $54.09M | $17.68M | $11.30M | $18.00M | 4.42× |
| 2015-09-30 | $79.19M | $15.71M | $48.08M | $20.79M | $10.32M | $15.90M | 5.04× |
| 2015-06-30 | $77.59M | $15.83M | $40.01M | $23.15M | $14.42M | $14.31M | 4.90× |
| 2015-03-31 | $69.16M | $13.18M | $31.21M | $23.26M | $14.69M | $12.24M | 5.25× |
| 2014-12-31 | $66.21M | $10.68M | $35.36M | $23.09M | $7.76M | $12.38M | 6.20× |
| 2014-09-30 | $61.13M | $10.47M | $35.91M | $18.17M | $7.05M | $13.34M | 5.84× |
| 2014-06-30 | $59.03M | $8.82M | $33.76M | $16.27M | $9.00M | $12.82M | 6.70× |
| 2014-03-31 | $75.80M | $7.12M | $49.21M | $21.55M | $5.04M | $11.44M | 10.64× |
| 2013-12-31 | $66.57M | $11.30M | $39.83M | $21.79M | $4.95M | $11.80M | 5.89× |
| 2013-09-30 | $69.31M | $8.78M | $42.24M | $20.75M | $6.32M | $10.06M | 7.89× |
| 2013-06-30 | $63.02M | $10.22M | $37.33M | $20.81M | $4.87M | $10.56M | 6.17× |
| 2013-03-31 | $54.82M | $8.89M | $28.57M | $19.34M | $6.91M | $10.26M | 6.16× |
| 2012-12-31 | $44.21M | $10.75M | $29.21M | $10.85M | $4.16M | $11.14M | 4.11× |
| 2012-09-30 | $37.94M | $9.04M | $18.39M | $11.92M | $7.64M | $10.77M | 4.20× |
| 2012-06-30 | $36.19M | $9.73M | $15.88M | $12.50M | $7.81M | $11.50M | 3.72× |
| 2012-03-31 | $32.16M | $8.79M | $12.79M | $15.11M | $4.25M | $13.85M | 3.66× |
| 2011-12-31 | $29.41M | $7.46M | $11.17M | $15.42M | $2.83M | $13.36M | 3.94× |
| 2011-09-30 | $53.84M | $4.15M | $10.50M | $39.32M | $4.02M | $2.46M | 12.96× |
| 2011-06-30 | $46.10M | $3.72M | $7.47M | $36.11M | $2.52M | $2.69M | 12.41× |
| 2011-03-31 | $50.88M | $4.62M | $14.20M | $35.42M | $1.26M | $1.95M | 11.01× |
| 2010-12-31 | (m) | (m) | $9.79M | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | $15.16M | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | $8.33M | (m) | (m) | (m) | (m) |
| 2010-03-31 | (m) | (m) | $12.53M | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | $5.04M | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |